Project Grant HT94252510057
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$473K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This federal Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) provides $2,531,888 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study "CORRECTING CYTOSKELETAL ABNORMALITIES AND PODOCYTE VULNERABILITY IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS." The 4-year award, starting on May 1, 2024, supports Bidmc's research aimed at improving treatments for this kidney disorder. As a leading academic medical center, Bidmc has an...
The Department of the Army Medical Command awarded a $2,455,660 project grant to Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) to support research on "TRANSCRIPTION FACTORS AS THERAPEUTIC TARGETS IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS." The period of performance for this award is from September 30, 2022 through September 29, 2026. The grant is being funded through the Military Medical Research and Development program (CFDA 12.420). This program aims to transform...
This federal Project Grant award of $1,442,061.00, awarded on April 1, 2024 by the Defense Health Agency, supports research under the Military Medical Research and Development program (CFDA 12.420) to investigate the role of podocyte ceramide synthase 6 in focal segmental glomerulosclerosis (FSGS). The primary awardee, the University of Texas Health Science Center at San Antonio, will conduct basic, translational, and clinical research to determine how genetic and toxin-induced FSGS affects...
The federal Project Grant award, identified as HT94252510088, is provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award, totaling $1,618,114.00, supports research conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital) to define the role of anti-nephrin antibodies in the recurrence of focal segmental glomerulosclerosis post transplantation. This 3-year research project, with a period of...
This Cooperative Agreement award from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program provides funding of $1,028,005.00 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) in Boston, MA. The award supports BIDMC's role as a clinical trials site for the Kidney Cancer Research Consortium, advancing research and interventions in kidney cancer. The award provides funding for the initial performance period from September 15, 2024 through...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
This Project Grant award of $1,723,552.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (BIDMC) to target specific long non-coding RNAs (lncRNAs) in novel combined therapies. The goal is to modulate the TSP1-dependent immune microenvironment vulnerabilities in advanced thyroid cancer. The research, spanning from September 1, 2025 to August 31, 2028, aims to...
This federal Project Grant award of $518,700.00 was made by the Defense Health Agency on July 1, 2024 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, MA. The award is part of the Military Medical Research and Development (CFDA 12.420) program, which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the broader public. The funding will support Bidmc's project titled "EXPLOITING DISRUPTION IN TRANSCRIPTIONAL...
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
The federal Project Grant award of $5,099,737.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a myeloid-targeted novel therapeutic for glomerular diseases. The award, with a performance period from July 1, 2025 to June 30, 2029, was granted to 149 Bio LLC, a for-profit organization located in Miami, Florida. The funded research aims to transform healthcare for military service members, veterans, and the broader public...